AbbVie’s blockbuster rheumatoid arthritis drug Humira will see even more competition next year, as AbbVie and biosimilar developer Alvotech settled a court dispute over when the company’s adalimumab biosimilar can launch, even as the drug has yet to be approved by the FDA.
The settlement fully resolves all pending legal...
